A California Question: How to Turn Billions of Dollars into Revolutionary Gene and Stem Cell Therapies?
By David Jensen,
California Stem Cell Report
| 02. 10. 2026
Touchy issues involving accusations that California’s $12 billion gene and stem cell research agency is pushing aside “good science” in favor of new priorities and preferences will be aired again in late March at a public meeting in Sacramento.
The concerns from scientists generally received a sympathetic hearing late last month from a number of directors of the California Institute for Regenerative Medicine (CIRM), which deals primarily with funding stem cell and genetic research.
The stakes are high. The issues involve standards for handing out billions of dollars in research awards and whether the research will actually lead — sooner rather than later — to therapies available to the general public. The fate of CIRM is on the table.
CIRM’s cash is expected to run out in about five years. Before that happens, CIRM backers will have to mount a new ballot initiative for more billions of taxpayer dollars if CIRM is to remain alive. The best chance of winning approval would be the general election of 2028. And CIRM needs results that resonate with voters to win...
Related Articles
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
Cathy Tie seems to be good at starting businesses but not so dedicated to maintaining them. CGS, like many others, first heard of her thanks to Caiwei Chen and Antonio Regalado in MIT Technology Review, May 2025, as the partner (perhaps bride) of the notorious Chinese scientist He Jiankui, described in the headline as “China’s Frankenstein.” He prefers “Chinese Darwin.” She ran his Twitter account for a while, contributing such gems as:
Get in luddite, we’re going gene editing...
By Laura DeFrancesco, Nature Biotechnology | 03.17.2026
The first gene editors designed to fix genetic lesions in mutation-agnostic ways are poised to enter the clinic. Tessera Therapeutics and Alltrna, two Flagship Pioneering-funded companies, are gearing up to test novel genetic medicines in humans. Tessera received regulatory clearance...
By Darren Incorvaia, Fierce Biotech | 03.11.2026
A new method for safely inserting large chunks of DNA into genomes has now measured up in mice, potentially paving the way for the next generation of gene editing medicines.
The approach, which is described in a Nature paper...
